Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

  title={Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma},
  author={Martin F. Orth and Julia S. Gerke and Thomas Kn{\"o}sel and A. Altendorf-Hofmann and Julian Musa and Rebeca Alba-Rubio and Stefanie Stein and Tilman L. B. H{\"o}lting and Florencia Cidre-Aranaz and Laura Romero-P{\'e}rez and Marlene Dallmayer and Michaela C. Baldauf and Aruna Marchetto and Giuseppina Sannino and Maximilian M. L. Knott and Fabienne S. Wehweck and Shunya Ohmura and Jing Li and Michiyuki Hakozaki and T. Kirchner and Thomas Dandekar and Elke Butt and Thomas G. P. Gr{\"u}newald},
  journal={International Journal of Cancer},
Soft‐tissue sarcomas are rare, heterogeneous, and often aggressive mesenchymal cancers. Many of them are associated with poor outcome, partially because biomarkers that can identify high‐risk patients are lacking. Studies on sarcomas are often limited by small sample‐sizes rendering the identification of biomarkers difficult when focusing on individual cohorts. However, the increasing number of publicly available ‘omics’ data opens inroads to overcome this obstacle. 
Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy
This is the first study to associate SIRT1 overexpression with a statistically significant prolongation of OS in HR-STS, and the combination of high Sirt1 and low TOP2A (“Top survivors”) significantly predicted a better OS compared to other biomarker combinations.
Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma
A novel UPS cell line is established using a surgically resected tumor from a patient with radiation-associated UPS and it is identified that the histone deacetylase inhibitor, romidepsin, is highly effective on NCC-UPS3-C1 cells.
Development and validation of prognostic markers in sarcomas base on a multi-omics analysis
Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
A Prognostic Model Based on Six Metabolism-Related Genes in Colorectal Cancer
The prognostic model and the clinical characteristics in a nomogram were combined to predict the overall survival of CRC patients and gene set enrichment analysis was conducted to identify the enriched Kyoto Encyclopedia of Genes and Genomes pathways in the high- and low-risk groups, which might provide novel therapeutic targets for patients.
A scoping review and proposed workflow for multi-omic rare disease research
This scoping review emphasises the value of multi-omic analysis for rare disease research in several ways compared to single omic analysis, ranging from the provision of a diagnosis, identification of prognostic biomarkers, distinct molecular subtypes (particularly for rare cancers), and identification of novel therapeutic targets.
Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women
The study suggests that replication across multiple ancestry populations can help improve the understanding of breast cancer genetics and identify causal variants.
Creatine metabolism: energy homeostasis, immunity and cancer biology
The role of creatine in adipocyte thermogenesis, immunity and cancer cell survival is discussed, suggesting that the pro-cancer role of Creatine is independent of its function in energy buffering.
Issue Information
The Journal is indexed by Biological Abstracts, BIOSIS Previews, Chemical Abstracts Service/SciFinder, CSA Biological Sciences Database, and Current Awareness in Biological Sciences.


MFH and high‐grade undifferentiated pleomorphic sarcoma—what's in a name?
The goal was to determine the presence of clinical prognostic implications that have evolved with this new nomenclature high‐grade undifferentiated pleomorphic sarcoma (HGUPS).
Diagnosis and management of pleomorphic sarcomas (so‐called “MFH”) in adults
The existence of “malignant fibrous histiocytoma” (“MFH”) as a distinct entity is controversial, and many tumors in this group afforded better prognostication, but traditional treatments still apply.
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.
  • B. Widemann, A. Italiano
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
The current knowledge of the epidemiology, clinical presentation, treatment, and pathogenesis of these tumors is described and ongoing and future research is highlighted.
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
A prognostic gene expression signature, complexity index in sarcomas (CINSARC), composed of 67 genes related to mitosis and chromosome management, is established, which predicts metastasis outcome and predicts outcome for gastrointestinal stromal tumors, breast carcinomas and lymphomas.
Neoadjuvant Therapy for Soft-Tissue Sarcomas.
Current neoadjuvant treatment options for soft-tissue sarcomas are discussed, with involvement of a surgical oncologist in addition to medical and radiation oncologists, and remains an area of controversy.
Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma
Data is examined that support or refute the use of adjuvant chemotherapy in the treatment of soft-tissue sarcomas.
Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2.
FPS-1 cells might be useful for investigating biological behavior and developing new molecular targeting antitumor drugs for UPS with EGFR or COX-2 expression.